Yann Mazabraud, Executive Vice President, Head of International, on August 12, 2026, sold 57,000 shares in Rhythm Pharmaceuticals (RYTM) for $6,620,575. Following the Form 4 filing with the SEC, Mazabraud has control over a total of 55,655 common shares of the company, with 55,655 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1649904/000164990426000007/xslF345X05/form4.xml
Harley G. Lappin, Director, on August 13, 2026, sold 25,032 shares in Corecivic (CXW) for $825,567. Following the Form 4 filing with the SEC, Lappin has control over a total of 50,328 common shares of the company, with 50,328 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1070985/000119312526352736/xslF345X05/ownership.xml
Paul T Quinlan, General Counsel, on August 14, 2026, sold 52,000 shares in Oruka Therapeutics (ORKA) for $5,641,409. Following the Form 4 filing with the SEC, Quinlan has control over a total of 31,034 common shares of the company, with 31,034 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/907654/000090765426000077/xslF345X05/form4.xml
Howard T Slayen, Director, on August 14, 2026, sold 5,700 shares in Aehr Test Systems (AEHR) for $758,264. Following the Form 4 filing with the SEC, Slayen has control over a total of 140,667 common shares of the company, with 140,667 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1040470/000104047026000257/xslF345X05/primary_01.xml